ABIO ARCA biopharma Inc.

2.69
-0.1  -4%
Previous Close 2.79
Open 2.72
Price To Book 0.56
Market Cap 4,288,048
Shares 1,594,070
Volume 10,944
Short Ratio
Av. Daily Volume 29,845
Stock charts supplied by TradingView

NewsSee all news

  1. ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update

    U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted GencaroPRECISION-AF clinical trial initiation anticipated fourth quarter of 2020Trial to

  2. ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020Trial to examine atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies WESTMINSTER,

  3. ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium

    WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for

  4. Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting

    WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial to be initiated 4Q 2020 subject to financing.
Gencaro
Chronic Heart Failure

Latest News

  1. ARCA biopharma Announces Fiscal Year 2019 Financial Results and Provides Corporate Update

    U.S. FDA Special Protocol Assessment agreement for a single pivotal Phase 3 clinical trial (PRECISION-AF) of genetically-targeted GencaroPRECISION-AF clinical trial initiation anticipated fourth quarter of 2020Trial to

  2. ARCA Biopharma Announces Third Quarter 2019 Financial Results and Provides Corporate Update

    PRECISION-AF pivotal Phase 3 clinical trial initiation anticipated first quarter of 2020Trial to examine atrial fibrillation in a heart failure population for which there are no FDA indicated drug therapies WESTMINSTER,

  3. ARCA Biopharma President and CEO Dr. Michael Bristow to Present at HFSA 2019 Excellence in Translational Science Symposium

    WESTMINSTER, Colo., Sept. 12, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for

  4. Arca Biopharma Announces Gencaro Atrial Fibrillation Clinical Data Selected for Presentation at HFSA 2019 Scientific Meeting

    WESTMINSTER, Colo., Sept. 11, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (NASDAQ:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for